Table 3.
Treatment characteristics: overall SABA use
| Italy | Germanya | Spain | Sweden | UK | |
|---|---|---|---|---|---|
| Mean (SD) number of annual SABA canisters | 3.1 (4.0) | 1.6 (3.9) | 3.3 (3.6) | 1.9 (2.9) | 4.2 (5.1) |
| Individuals with 0–2 SABA canisters/year (%) | 91 | 84 | 71 | 70 | 62 |
| Individuals with ≥ 3 SABA canisters/year (%) | 9 | 16 | 29 | 30 | 38 |
| Individuals with 3–6 SABA canisters/year (%) | 6 | 10 | 19 | 25 | 24 |
| Individuals with 7–12 SABA canisters/year (%) | 2 | 3 | 6 | 5 | 11 |
| Individuals with ≥ 13 SABA canisters/year (%) | 1 | 2 | 4 | 1 | 4 |
GP general practitioner, SABA short acting β2-agonist, SD standard deviation
aThis analysis was based on GP-treated individuals only (n = 29,636)